Wegovy Pill Crosses 3 Million Prescriptions in Just Five Months: Novo Nordisk's Obesity Bet Pays Off
Oral GLP-1 therapy is bringing obesity treatment to millions of patients who had never used weight-loss medicines before
The obesity treatment landscape is changing at remarkable speed, and Novo Nordisk has just added another milestone to the story.
The Danish pharmaceutical giant announced that Wegovy® (semaglutide) tablets 25 mg have surpassed 3 million prescriptions in the United States within just over five months of launch, making it one of the strongest pharmaceutical product launches by prescription volume in recent U.S. history.




About Authors

Harsh Bhardwaj1*, Sakshi Jain2, Raaz K Maheshwari3



Vinay Kumar Singh.


